n,n-dimethylarginine has been researched along with zofenopril in 1 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (zofenopril) | Trials (zofenopril) | Recent Studies (post-2010) (zofenopril) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 162 | 40 | 60 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | zofenopril (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Condorelli, M; de Nigris, F; Ignarro, LJ; Liguori, A; Napoli, C; Pignalosa, O; Sica, V | 1 |
1 trial(s) available for n,n-dimethylarginine and zofenopril
| Article | Year |
|---|---|
Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arginine; Captopril; Enalapril; Female; Humans; Hypertension; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Oxidative Stress | 2004 |